Inflammasomes and dermatology

Anais Brasileiros de Dermatologia

Volumn 91, Issue 5, 2016, Pages 566-578

  De Sá, Daniel Coelho ^a   Festa Neto, Cyro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hereditary autoinflammatory diseases; Immunity; Inflammasomes; Innate; Interleukin 1; Sweet s syndrome

Indexed keywords

INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA;

ACNE; ARTICLE; ATOPIC DERMATITIS; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; CINCA SYNDROME; CONTACT DERMATITIS; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNE RESPONSE; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS; MELANOMA; PAPA SYNDROME; PSORIASIS; SCHNITZLER SYNDROME; SKIN DISEASE; SUPPURATIVE HIDRADENITIS; VITILIGO; HEREDITARY PERIODIC FEVER; IMMUNOLOGY; PATHOLOGY;

HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INTERLEUKIN-1BETA; SKIN DISEASES;

EID: 84994620473     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20165577     Document Type: Article

References (131)

1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 2002;10: 417-26.
2. Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma. Cancer Lett. 2012;314: 24-33.
3. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev. 2011;243: 136-51.
4. de Zoete MR, Palm NW, Zhu S, Flavell RA. Inflammasomes. Cold Spring Harb Perspect Biol. 2014;6: a016287.
5. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21: 677-87.
6. Miao EA, Rajan JV, Aderem A. 2011. Caspase-1-induced pyroptotic cell death. Immunol Ver. 2011;243: 206-14.
7. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140: 821-32.
8. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166: 1-15.
9. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol. 2009;124: 1141-9; quiz 1150-1.
10. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012;481: 278-86.
11. Pontillo A, Catamo E, Arosio B, Mari D, Crovella S. NALP1/NLRP1 GeneticVariants are Associated With Alzheimer Disease. Alzheimer Dis Assoc Disord. 2012;26: 277-81.
12. Freeman LC, Ting JP. The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem. 2016;136 Suppl 1: 29-38.
13. Magitta NF, Bøe Wolff AS, Johansson S, Skinningsrud B, Lie BA, Myhr KM, et al. A codingpolymorphism in NALP1 confers risk for autoimmune Addison’s disease and type 1 diabetes. Genes Immun. 2009;10: 120-4
14. Pontillo A, Girardelli M, Kamada AJ, Pancotto JA, Donadi EA, Crovella S, et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity. 2012;45: 271-8.
15. Pontillo A, Oshiro TM, Girardelli M, Kamada AJ, Crovella S, Duarte AJ. Polymorphisms in inflammasome’ genes and susceptibility to HIV-1 infection. J Acquir Immune Defic Syndr. 2012;59: 121-5.
16. Dorhoi A, Nouailles G, Jörg S, Hagens K, Heinemann E, Pradl L, et al. Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis. Eur J Immunol.;42: 374-84.
17. Wu J, Fernandes-Alnemri T, Alnemri ES. Involvement of the AIM2, NLRC4, and NLRP3 inflammasomes in caspase-1 activation by Listeria monocytogenes. J Clin Immunol. 2010;30: 693-702.
18. Gavrilin MA, Wewers MD. Francisella Recognition by Inflammasomes: Differences between Mice and Men. Front Microbiol. 2011;2: 11.
19. Case CL, Shin S, Roy CR. Asc and Ipaf Inflammasomes direct distinct pathways for caspase-1 activation in response to Legionella pneumophila. Infect Immun. 2009;77: 1981-91.
20. Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, Tabeling C, et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol. 2011;187: 434-40.
21. Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. 2014;5: 12-20.
22. Liu R, Truax AD, Chen L, Hu P, Li Z, Chen J, et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget. 2015;6: 33456-69.
23. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006; 3: e297.
24. Yang CA, Chiang BL. Inflammasomes and human autoimmunity: A comprehensive review. J Autoimmun. 2015;61: 1-8.
25. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. Cell. 1999;97: 133-44.
26. Dávila-Seijo P, Hernández-Martín A, Torrelo A. Autoinflammatory syndromes for the dermatologist. Clin Dermatol. 2014;32: 488-501.
27. Moghaddas F, Masters SL. Monogenic autoinflammatory diseases: Cytokinopathies. Cytokine. 2015;74: 237-46.
28. Nguyen TV, Cowen EW, Leslie KS. Autoinflammation: From monogenic syndromes to common skin diseases. J Am Acad Dermatol. 2013;68: 834-53.
29. Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9: 232-46.
30. Sanchez GA, de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. Rheum Dis Clin North Am. 2013;39: 701-34
31. Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142: w13590.
32. Miyamae T. Cryopyrin-associated periodic syndromes: diagnosis and management. Paediatr Drugs. 2012;14: 109-17.
33. Nakamura Y, Kambe N. Linkage of bacterial colonization of skin and the urticarialike rash of NLRP3-mediated autoinflammatory syndromes through mast cellderived TNF-α. J Dermatol Sci. 2013;71: 83-8.
34. Aksentijevich I, Putnam CD, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The Clinical Continuum of Cryopyrinopathies: Novel CIAS1 Mutations in North American Patients and a New Cryopyrin Model. Arthritis Rheum. 2007;56: 1273-85.
35. Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep. 2011;11: 12-20.
36. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65: 223-44.
37. Abramovits W, Oquendo M. Introduction to autoinflammatory syndromes and diseases. Dermatol Clin. 2013;31: 363-85.
38. ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74: 1636-44.
39. E. Sohar, J. Gafni, M. Pras, H. Heller. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43: 227-53.
40. Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013;2013: 513782.
41. Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood. 2008; 112: 3563-73.
42. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic feversyndrome. The clinical spectrum in a series of 50 patients. Medicine (Baltimore). 1994;73: 133-44
43. C. Yoram, A.R. Padeh. Hyperimmunoglobulin-D syndrome: pathophysiology. © 2013. (2012) [UpToDate]
44. Smith EJ, Allantaz F, Bennett L, Zhang D, Gao X, Wood G, et al. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics. 2010;11: 519-27.
45. Hong JB, Su YN, Chiu HC. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2 BP1 gene. J Am Acad Dermatol. 2009;61: 533-5.
46. Look J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL. Genetic predisposition (NLRP3 V198m mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010; 125: 500-2.
47. Pizzirani C, Falzoni S, Govoni M, La Corte R, Donadei S, Di Virgilio F, et al. Dysfunctional inflammasome in Schnitzler’s syndrome. Rheumatology (Oxford). 2009;48: 1304-8.
48. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis. 2010;5: 38.
49. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-Receptor antagonist. N Engl J Med. 2009;360: 2426-37.
50. Jesus AA, Osman M, Silva CA, Kim PW, Pham TH, Gadina M, et al. A Novel Mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 2011;63: 4007-17.
51. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013;31: 405-25.
52. Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol. 2015 Jul 22.
53. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006;142: 1591-7.
54. Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet’s Syndrome. Dermatology. 2011;222: 123-7.
55. Delluc A, Limal N, Puéchal X, Francès C, Piette JC, Cacoub P: Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008;67: 278-9.
56. Nesterovitch AB, Hoffman MD, Simon M, Petukhov PA, Tharp MD, Glant TT. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol 2011; 36: 889-95.
57. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361: 496-509.
58. Rivas Bejarano JJ, Valdecantos WC. Psoriasis as autoinflammatory disease. Dermatol Clin. 2013;31: 445-60.
59. Carlström M, Ekman AK, Petersson S, Söderkvist P, Enerbäck C. Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol. 2012;21: 932-7.
60. Ekman AK, Verma D, Fredrikson M, Bivik C, Enerbäck C. Genetic variations of NLRP1: susceptibility in psoriasis. Br J Dermatol. 2014;171: 1517-20.
61. Johansen C, Moeller K, Kragballe K, Iversen L. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol. 2007;127: 2857-64.
62. Salskov-Iversen ML, Johansen C, Kragballe K, Iversen L. Caspase-5 Expression Is Upregulated in Lesional Psoriatic Skin. J Invest Dermatol. 2011;131: 670-6.
63. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Göss C, Anz D. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med. 2011;3: 82ra38.
64. Ortiz-Fernández L, García-Lozano JR, Montes-Cano MA, Conde-Jaldón M, Ortego-Centeno N, García-Hernández FJ. Variants of the IFI16 gene affecting the levels of expression of mRNA are associated with susceptibility to Behçet Disease. J Rheumatol. 2015;42: 695-701.
65. Yüksel Ş, Eren E, Hatemi G, Sahillioğlu AC, Gültekin Y, Demiröz D, et al. Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet’s syndrome patients. Int Immunol. 2014;26: 71-81.
66. Türe-Özdemir F, Tulunay A, Elbasi MO, Tatli I, Maurer AM, Mumcu G, et al. Proinflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behcet’s disease. Rheumatology (Oxford). 2013;52: 800-5.
67. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356: 1216-25
68. Jin Y, Birlea SA, Fain PR, Spritz RA. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol. 2007;127: 2558-62
69. Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci U.S.A. 2013;110: 2952-6
70. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, et al. Th17 Cells and Activated Dendritic Cells Are Increased in Vitiligo Lesions. PLoS ONE. 2011;6: e18907.
71. Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol. 2014;170: 816-23.
72. Pontillo A, Reis EC, Liphaus BL, Silva CA, Carneiro-Sampaio M. Inflammasome polymorphisms in juvenile systemic lupus erythematosus. Autoimmunity. 2015;48: 434-7.
73. Wang B, Zhu JM, Fan YG, Feng CC, Chen GM, Chen H, et al. The association of IL1α and IL1β polymorphisms with susceptibility to systemic lupus erythematosus: a meta-analysis. Gene. 2013; 527: 95-101.
74. Wen D, Liu J, Du X, Dong JZ, Ma CS. Association of interleukin-18 (-137G/C) polymorphism with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Int Rev Immunol. 2014;33: 34-44.
75. Wittmann M, Macdonald A, Renne J. IL-18 and skin inflammation. Autoimmun Rev. 2009;9: 45-8.
76. Wang D, Drenker M, Eiz-Vesper B, Werfel T, Wittmann M. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum. 2008;58: 3205-15.
77. Kahlenberg JM, Kaplan MJ. The Inflammasome and lupus- another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol. 2014;26: 475-81
78. van Bon L, Cossu M, Radstake TRDJ. An update on an immune system that goes awry in systemic sclerosis. Curr Opin in Rheumatol. 2011;23: 505-10.
79. Martínez-Godínez MA, Cruz-Domínguez MP, Jara LJ, Domínguez-López A, Jarillo-Luna RA, Vera-Lastra O, et al. Expression of NLRP3 Inflammasome, Cytokines and Vascular Mediators in the Skin of Systemic Sclerosis Patients. Isr Med Assoc J. 2015;17: 5-10.
80. Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD. The inflammasome activating caspase-1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. 2011; 63: 3563-74.
81. Rosen J, Friedman AJ. Inflammatory acne: new developments in pathogenesis and treatment. Cutis. 2014;94: 266-7.
82. Qin M, Pirouz A, Kim MH, Krutzik SR, Garbán HJ, Kim J. Propionibacterium acnes induces IL-1β secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol. 2014;134: 381-8.
83. Kistowska M, Gehrke S, Jankovic D, Kerl K, Fettelschoss A, Feldmeyer L, et al. IL-1β Drives Inflammatory Responses to Propionibacterium acnes In Vitro and In Vivo. J Invest Dermatol. 2014;134: 677-85
84. Li ZJ, Choi DK, Sohn KC, Seo MS, Lee HE, Lee Y, et al. Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes. J Invest Dermatol. 2014;134: 2747-56.
85. Casas C, Paul C, Lahfa M, Livideanu B, Lejeune O, Alvarez-Georges S, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012; 21: 906-910.
86. Salzer S, Kresse S, Hirai Y, Koglin S, Reinholz M, Ruzicka T, et al. Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: Possible implications for rosacea. J Dermatol Sci. 2014;76: 173-9.
87. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-β Br J Dermatol. 2011;164: 1292-98.
88. Lima AL, Karl I, Giner T, Poppe H, Schmidt M, Presser D, et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol. 2016;174: 514-21.
89. van der Zee HH, Prens EP. The Anti-Inflammatory Drug Colchicine Lacks Efficacy in Hidradenitis Suppurativa. Dermatology. 2011;223: 169-73
90. Li X, Zhong F. Nickel induces interleukin-1β secretion via the NLRP3-ASCcaspase-1 pathway. Inflammation. 2014;37: 457-66.
91. Watanabe H, Gaide O, Petrilli V, Martinon F, Contassot E, Roques S, et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol. 2007;127: 1956-63.
92. Martin SF, Esser PR, Weber FC, Jakob T, Freudenberg MA, Schmidt M, et al. Mechanisms of chemical induced innate immunity in allergic contact dermatitis. Allergy. 2011;66: 1152-63.
93. Abramovits W, Rivas Bejarano JJ, Valdecantos WC. Role of Interleukin 1 in Atopic Dermatitis. Dermatol Clin. 2013;31: 437-44
94. Krause K, Metz M, Makris M, Zuberbier T, Maurer M. The role of interleukin-1 in allergy-related disorders. Curr Opin Allergy Clin Immunol. 2012;12: 477-84
95. Niebuhr M, Baumert K, Heratizadeh A, Satzger I, Werfel T. Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu. Allergy. 2014;69: 1058-67.
96. Bivik C, Verma D, Winge MC, Lieden A, Bradley M, Rosdahl I, et al. Genetic Variation in the Inflammasome and Atopic Dermatitis Susceptibility. J Invest Dermatol. 2013;133: 2486-9.
97. Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, et al. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA. 2012;109: 18384-9.
98. Gasparoto TH, de Oliveira CE, de Freitas LT, Pinheiro CR, Hori JI, Garlet GP et al. Inflammasome Activation Is Critical to the Protective Immune Response during Chemically Induced Squamous Cell Carcinoma. PLoS One. 2014;9: e107170.
99. Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer HD. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes Curr Biol. 2007;17: 1140-5
100. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta, J Biol Chem. 2010;285: 6477-88.
101. Verma D, Bivik C, Farahani E, Synnerstad I, Fredrikson M, Enerbäck C, et al. Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma, Pigment Cell Melanoma Res. 2012;25: 506-13.
102. Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA, Fujita M. Dual role of apoptosisassociated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol. 2013;133: 518-27.
103. Gehrke S, Otsuka A, Huber R, Meier B, Kistowska M, Fenini G, et al. Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages. J Dermatol Sci. 2014;74: 167-9.
104. Ahmad I, Muneer KM, Tamimi IA, Chang ME, Ata MO, Yusuf N. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol Appl Pharmacol. 2013;270: 70-6.
105. Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun. 2011;414: 551-6.
106. van de Veerdonk FL, Joosten LA, Netea MG. The interplay between inflammasome activation and antifungal host defense. Immunol Rev. 2015;265: 172-80.
107. Kistowska M, Fenini G, Jankovic D, Feldmeyer L, Kerl K, Bosshard P, et al. Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signalling. Exp Dermatol. 2014;23: 884-89
108. Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA, Brown GD, et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe. 2009;5: 487-97.
109. Tomalka J, Ganesan S, Azodi, Patel K, Majmudar P, Hall BA, et al. A Novel Role for the NLRC4 Inflammasome in Mucosal Defenses against the Fungal Pathogen Candida albicans. PLoS Pathog. 2011;7: e1002379.
110. Joly S, Ma N, Sadler JJ, Soll DR, Cassel SL, Sutterwala FS. Cutting edge: Candida albicans hyphae formation triggers activation of the Nlrp3 inflammasome. J Immunol. 2009;183: 3578-81
111. Cheng SC, van de Veerdonk FL, Lenardon M, Stoffels M, Plantinga T, Smeekens S, et al. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol. 2011;90: 357-66.
112. Mao L, Zhang L, Li H, Chen W, Wang H, Wu S, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun. 2014;82: 882-92.
113. Li H, Wu S, Mao L, Lei G, Zhang L, Lu A, et al. Human pathogenic fungus Trichophyton schoenleinii activates the NLRP3 inflammasome. Protein Cell. 2013;4: 529-38.
114. Gonçalves AC, Maia DC, Ferreira LS, Monnazzi LG, Alegranci P, Placeres MC, et al. Involvement of major components from Sporothrix schenckii cell wall in the caspase-1 activation, nitric oxide and cytokines production during experimental sporotrichosis. Mycopathologia. 2015;179: 21-30
115. Nour AM, Reichelt M, Ku CC, Ho MY, Heineman TC, Arvin AM. Varicella-Zoster Virus Infection Triggers Formation of an Interleukin-1β (IL-1β)-processing Inflammasome Complex. J Biol Chem. 2011;286: 17921-33.
116. Reinholz M, Kawakami Y, Salzer S, Kreuter A, Dombrowski Y, Koglin S, et al. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res. 2013;305: 723-32.
117. Kerur N, Veettil MV, Sharma-Walia N, Bottero V, Sadagopan S, Otageri P, et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi sarcoma associated herpesvirus infection. Cell Host Microbe. 2011;9: 363-75.
118. K.E. Johnson, L. Chikoti, Chandran B. Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. J Virol. 2013;87: 5005-18.
119. Krishna S, Miller LS. Innate and adaptive immune responses against Staphylococcus aureus skin infections. Semin Immunopathol. 2012;34: 261-80
120. Cho JS, Guo Y, Ramos RI, Hebroni F, Plaisier SB, Xuan C, et al. Neutrophil-derived IL-1β Is Sufficient for Abscess Formation in Immunity against Staphylococcus aureus in Mice. PLoS Pathog. 2012;8: e1003047.
121. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, et al. Staphylococcus aureus α-Hemolysin Activates the NLRP3-Inflammasome in Human and Mouse Monocytic Cells. PLoS One. 2009;4: e7446
122. Li W, Katz BP, Bauer ME, Spinola SM. Haemophilus ducreyi Infection Induces Activation of the NLRP3 Inflammasome in Nonpolarized but Not in Polarized Human Macrophages. Infect Immun. 2013;81: 2997-3008.
123. Novais FO, Carvalho LP, Passos S, Roos DS, Carvalho EM, Scott P, et al. Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology. J Invest Dermatol. 2015;135: 94-101.
124. Stojadinovic O, Minkiewicz J, Sawaya A, Bourne JW, Torzilli P, de Rivero Vaccari JP, et al. Deep tissue injury in development of pressure ulcers: a decrease of inflammasome activation and changes in human skin morphology in response to aging and mechanical load. PLoS One. 2013;8: e69223
125. Hu Y, Liang D, Li X, Liu HH, Zhang X, Zheng M, et al. The Role of Interleukin-1 in Wound Biology. Part I: Murine In Silico and In Vitro Experimental Analysis. Anesth Analg. 2010;111: 1525-33.
126. Bitto A, Altavilla D, Pizzino G, Irrera N, Pallio G, Colonna MR, et al. Inhibition of inflammasome activation improves the impaired pattern of healing in genetically diabetic mice. Br J Pharmacol. 2014;171: 2300-7.
127. Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained Inflammasome Activity in Macrophages Impairs Wound Healing in Type 2 Diabetic Humans and Mice. Diabetes. 2014; 63: 1103-14.
128. Weinheimer-Haus EM, Mirza RE, Koh TJ. Nod-Like Receptor Protein-3 Inflammasome Plays an Important Role during Early Stages of Wound Healing. PLoS One. 2015;10: e0119106.
129. Weston JK, Uetrecht J. Activation of inflammasomes by agents causing idiosyncratic skin reactions: a possible biomarker. Chem Res Toxicol. 2014;27: 949-51.
130. Zhang X, Sharma AM, Uetrecht J. Identification of danger signals in nevirapineinduced skin rash. Chem Res Toxicol. 2013;26: 1378-83.
131. de Rivero Vaccari JP, Sawaya ME, Brand F 3rd, Nusbaum BP, Bauman AJ, Bramlett HM, et al. Caspase-1 Level Is Higher in the Scalp in Androgenetic Alopecia Dermatol Surg. 2012;38(7 Pt 1): 1033-9.